HWAM
ALLO icon

Hennion & Walsh Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Hennion & Walsh Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.66M Buy
1,039,328
+316,400
+44% +$602K 0.05% 440
2026
Q2 		$1.5M Buy
+722,928
New +$1.59M 0.04% 460

Other funds holding ALLO

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
AIA
Arcadia Investment Advisors Eagle, Idaho $241M AUM 11.84% 1-Year Est. Return

Hennion & Walsh Asset Management's ALLO Position: Q3 2026 in Review

Hennion & Walsh Asset Management increased its Allogene Therapeutics (ALLO) stake by 44% in Q3 2026, buying an estimated $602K and bringing the position to 1,039,328 shares worth $1.66M. The position accounts for 0.05% of the portfolio, ranked #440.

Hennion & Walsh Asset Management first reported a position in ALLO in Q2 2026 and has held it in 2 quarters since. 7 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • Hennion & Walsh Asset Management held 1,039,328 shares of Allogene Therapeutics worth $1.66M as of Q3 2026.
  • Hennion & Walsh Asset Management bought 316,400 Allogene Therapeutics shares in Q3 2026, an estimated $602K.
  • Allogene Therapeutics made up 0.05% of Hennion & Walsh Asset Management's portfolio in Q3 2026, its #440 holding.
  • Hennion & Walsh Asset Management first reported a position in Allogene Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 7 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q3 2026, filed 13 Oct 2026.